Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. DNTH
stocks logo

DNTH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
398.09K
-69.96%
-1.078
+33.14%
199.43K
-82.85%
-0.906
+10.52%
213.71K
+10.73%
-0.926
+5.26%
Estimates Revision
The market is revising Downward the revenue expectations for Dianthus Therapeutics, Inc. (DNTH) for FY2025, with the revenue forecasts being adjusted by -11.72% over the past three months. During the same period, the stock price has changed by 68.72%.
Revenue Estimates for FY2025
Revise Downward
down Image
-11.72%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+7.02%
In Past 3 Month
Stock Price
Go Up
up Image
+68.72%
In Past 3 Month
Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is 69.15 USD with a low forecast of 44.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is 69.15 USD with a low forecast of 44.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.710
sliders
Low
44.00
Averages
69.15
High
100.00
Current: 44.710
sliders
Low
44.00
Averages
69.15
High
100.00
H.C. Wainwright
Buy
maintain
$40 -> $47
2025-11-10
Reason
H.C. Wainwright
Price Target
$40 -> $47
2025-11-10
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Dianthus to $47 from $40 and keeps a Buy rating on the shares. The firm sees a "catalyst-rich" 2026 for the company.
Truist
Danielle Brill
Buy
initiated
$56
2025-10-14
Reason
Truist
Danielle Brill
Price Target
$56
2025-10-14
initiated
Buy
Reason
Truist analyst Danielle Brill initiated coverage of Dianthus with a Buy rating and $56 price target. The recent Phase 2 proof-of-concept results with claseprubart in generalized myasthenia gravis were overall supportive of the thesis that Dianthus' differentiated approach to targeting the autoantibody mediated complement cascade may offer similar efficacy as available complement inhibitors, but with a cleaner safety profile, says the analyst, who also thinks the gMG data are relatively de-risking for the ongoing Phase 3 chronic inflammatory demyelinating polyneuropathy trial.
Clear Street
Bill Maughan
initiated
$100
2025-09-16
Reason
Clear Street
Bill Maughan
Price Target
$100
2025-09-16
initiated
Reason
Clear Street analyst Bill Maughan initiated coverage of Dianthus with a Buy rating and $100 price target. Dianthus is a biotech company primarily developing claseprubart for the treatment of complement-driven autoimmune diseases, the analyst tells investors in a research note. The firm believes claseprubart is a "best-in-class" complement inhibitor that is well positioned to improve on the standard of care in each of the three indications currently being tested in the clinic. It sees $1B-$2B of sales potential in each of these opportunities.
Wedbush
Outperform
maintain
$42 -> $44
2025-09-12
Reason
Wedbush
Price Target
$42 -> $44
2025-09-12
maintain
Outperform
Reason
Wedbush raised the firm's price target on Dianthus to $44 from $42 and keeps an Outperform rating on the shares. The firm is incorporating the recent $288M secondary offering into its estimates. Wedbush's model also incorporates the over-allotment and while it previously modeled a raise in early 2026, this would appear to be larger in magnitude versus its prior assumptions. With the proceeds from the offering, Dianthus management anticipates cash/equivalents now extend runway into 2028. With Phase 2 MaGiC data in hand, the firm looks ahead to the second half of 2026 for additional top-line readouts from the claseprubart CIDP and MMN programs.
Stifel
Alex Thompson
Buy
maintain
$52 -> $65
2025-09-12
Reason
Stifel
Alex Thompson
Price Target
$52 -> $65
2025-09-12
maintain
Buy
Reason
Stifel analyst Alex Thompson raised the firm's price target on Dianthus to $65 from $52 and keeps a Buy rating on the shares following the positive Phase 2 MaGic trial in AChR+ Myasthenia Gravis. Following the data, the firm's model now reflects higher MG odds of success of 75%, up from a prior 50% forecast, the analyst noted.
Baird
NULL -> Outperform
upgrade
$50 -> $67
2025-09-09
Reason
Baird
Price Target
$50 -> $67
2025-09-09
upgrade
NULL -> Outperform
Reason
Baird raised the firm's price target on Dianthus to $67 from $50 and keeps an Outperform rating on the shares. The firm said they are positive on the company's Phase 2 MaGic data profile in gMG supporting a differentiated profile.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Dianthus Therapeutics Inc (DNTH.O) is -11.52, compared to its 5-year average forward P/E of -7.69. For a more detailed relative valuation and DCF analysis to assess Dianthus Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-7.69
Current PE
-11.52
Overvalued PE
-5.01
Undervalued PE
-10.36

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
392.69
Current PS
0.00
Overvalued PS
776.25
Undervalued PS
9.13
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 954.27% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 954.27% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

DNTH News & Events

Events Timeline

(ET)
2025-11-05
16:08:28
Dianthus Announces Q3 Earnings Per Share of 97 Cents, Exceeding Consensus Estimate of 90 Cents
select
2025-10-16 (ET)
2025-10-16
07:05:07
Dianthus Signs Exclusive Licensing Deal with Leads Biolabs for DNTH212
select
2025-09-09 (ET)
2025-09-09
23:20:37
Dianthus Sets Secondary Offering Price at $33.00 for 6.49 Million Shares
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-24Benzinga
The Insider Report: Get Ready for the Upcoming Buying Opportunity During the Next Market Dip

  • Market Overview: The stock market is experiencing turbulence, with the Nasdaq down 2.74% and a notable rotation into healthcare, which is currently the only sector showing strong opportunities. The crypto market is facing significant challenges, indicating a critical juncture ahead.

  • Dianthus Therapeutics: Dianthus Therapeutics (DNTH) is a clinical-stage biotech company focused on innovative therapies for autoimmune diseases, showing potential for a 95% return. Despite a high Price-to-Sales ratio, recent technical patterns suggest an upward momentum.

  • Daqo New Energy: Daqo New Energy (DQ), a leading polysilicon manufacturer for solar products, presents a 78% return potential. The company is well-positioned to benefit from the growing renewable energy sector, with strong operational resilience and strategic expansion plans.

  • Arcus Biosciences: Arcus Biosciences (RCUS) is developing advanced cancer therapies, with a 45% return potential. The company is backed by significant partnerships and funding, allowing it to aggressively pursue its pipeline while navigating the biotech landscape.

[object Object]
Preview
4.0
11-10Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Dianthus Therapeutics and Increases Price Target to $47

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Success: Traders utilize Benzinga Pro's resources to gain an edge in the markets, aiming for successful trading outcomes.

[object Object]
Preview
9.0
10-30Newsfilter
Dianthus Therapeutics Showcases New Claseprubart Findings at the 2025 AANEM Annual Meeting

  • Phase 2 MaGic Trial Results: Positive data from the Phase 2 MaGic trial of claseprubart in generalized Myasthenia Gravis (gMG) was presented, showing significant improvements in MG-ADL and QMG scores, supporting the potential for a 300mg/2mL Q4W dosing regimen.

  • Upcoming Phase 3 Trial: A Phase 3 trial for claseprubart is planned to start in 2026, featuring two treatment arms (300mg/2mL Q2W and Q4W) and including patients with a QMG score of 10 or higher.

  • Efficacy of Complement Inhibition: New preclinical data suggest that upstream complement inhibition (active C1s) may offer greater efficacy compared to downstream inhibition (C5), highlighting the potential advantages of claseprubart.

  • Dianthus Therapeutics Overview: Dianthus Therapeutics is focused on developing innovative therapies for severe autoimmune diseases, with plans for multiple clinical trials in the near future, including studies in Chronic Inflammatory Demyelinating Polyneuropathy and Multifocal Motor Neuropathy.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dianthus Therapeutics Inc (DNTH) stock price today?

The current price of DNTH is 44.71 USD — it has increased 1.68 % in the last trading day.

arrow icon

What is Dianthus Therapeutics Inc (DNTH)'s business?

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

arrow icon

What is the price predicton of DNTH Stock?

Wall Street analysts forecast DNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNTH is 69.15 USD with a low forecast of 44.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dianthus Therapeutics Inc (DNTH)'s revenue for the last quarter?

Dianthus Therapeutics Inc revenue for the last quarter amounts to 396.00K USD, decreased -81.77 % YoY.

arrow icon

What is Dianthus Therapeutics Inc (DNTH)'s earnings per share (EPS) for the last quarter?

Dianthus Therapeutics Inc. EPS for the last quarter amounts to -0.97 USD, increased 31.08 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dianthus Therapeutics Inc (DNTH)'s fundamentals?

The market is revising Downward the revenue expectations for Dianthus Therapeutics, Inc. (DNTH) for FY2025, with the revenue forecasts being adjusted by -11.72% over the past three months. During the same period, the stock price has changed by 68.72%.
arrow icon

How many employees does Dianthus Therapeutics Inc (DNTH). have?

Dianthus Therapeutics Inc (DNTH) has 78 emplpoyees as of December 05 2025.

arrow icon

What is Dianthus Therapeutics Inc (DNTH) market cap?

Today DNTH has the market capitalization of 1.92B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free